Complex pattern of immune evasion in MSI colorectal cancer

References

• Kloor M, Staffa L, Ahadova A, Von Knebel Doeberitz M. Clinical significance of microsatellite instability in colorectal cancer. Langenbeck's Archives of Surgery. 2014;399(1):23–31. doi:10.1007/s00423-013-1112-3. PMID:24048684
   PubMed Web of Science ®Google Scholar
• Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and Familial Colon Cancer. Gastroenterology. 2010;138(6):2044–58. doi:10.1053/j.gastro.2010.01.054. PMID:20420945
   PubMed Web of Science ®Google Scholar
• Kloor M, Von Knebel Doeberitz M. The immune biology of microsatellite-unstable cancer. Trends Cancer. 2016;2(3):121–33. doi:10.1016/j.trecan.2016.02.004. PMID:28741532
   PubMed Web of Science ®Google Scholar
• Buckowitz A, Knaebel H-P, Benner A, Bläker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br J Cancer. 2005;92(9):1746–53. doi:10.1038/sj.bjc.6602534. PMID:15856045
   PubMed Web of Science ®Google Scholar
• Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, Vecchiato N, Macrì E, Fornasarig M, Boiocchi M. High Prevalence of Activated Intraepithelial Cytotoxic T Lymphocytes and Increased Neoplastic Cell Apoptosis in Colorectal Carcinomas with Microsatellite Instability. Am J Pathol. 1999;154(6):1805–13. doi:10.1016/S0002-9440(10)65436-3. PMID:10362805
   PubMed Web of Science ®Google Scholar
• Lee K, Tosti E, Edelmann W. Mouse models of DNA mismatch repair in cancer research. DNA Repair. 2016;38:140–6. doi:10.1016/j.dnarep.2015.11.015. PMID:26708047
   PubMed Web of Science ®Google Scholar
• Lee V, Murphy A, Le DT, Diaz LA. Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade. The Oncologist. 2016;21(10):1200–11. doi:10.1634/theoncologist.2016-0046. PMID:27412392
   PubMed Web of Science ®Google Scholar
• Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509–20. doi:10.1056/NEJMoa1500596. PMID:26028255
   PubMed Web of Science ®Google Scholar
• Teixidó C, González-Cao M, Karachaliou N, Rosell R. Predictive factors for immunotherapy in melanoma. Ann Trans Med. 2015;3(15):208. doi:10.3978/j.issn.2305-5839.2015.05.07 PMID:26488004
   PubMed Web of Science ®Google Scholar
• Kloor M, Michel S, von Knebel Doeberitz M. Immune evasion of microsatellite unstable colorectal cancers. Int J Cancer. 2010;127(5):1001–10. doi:10.1002/ijc.25283. PMID:20198617
   PubMed Web of Science ®Google Scholar
• Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Karran P. Selection for beta 2-microglobulin mutation in mismatch repair-defective colorectal carcinomas. Curr Biol. 1996;6(12):1695–7. doi:10.1016/S0960-9822(02)70795-1. PMID:8994836
   PubMed Web of Science ®Google Scholar
• Kloor M, von Knebel Doeberitz M, Gebert JF. Molecular testing for microsatellite instability and its value in tumor characterization. Expert review of molecular diagnostics. 2005;5(4):599–611. doi:10.1586/14737159.5.4.599. PMID:16013977
   PubMed Web of Science ®Google Scholar
• Kloor M, Michel S, Buckowitz B, Rüschoff J, Büttner R, Holinski-Feder E, Dippold W, Wagner R, Tariverdian M, Benner A, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer. 2007;121(2):454–8. doi:10.1002/ijc.22691. PMID:17373663
   PubMed Web of Science ®Google Scholar
• Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jiménez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, et al. Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens. 1998;52(6):520–9. doi:10.1111/j.1399-0039.1998.tb03082.x. PMID:9894850
   PubMedGoogle Scholar
• Echterdiek F, Janikovits J, Staffa L, Müller M, Lahrmann B, Frühschütz M, Hartog B, Nelius N, Benner A, Tariverdian M, et al. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. OncoImmunology. 2016;5(2):e1075692. doi:10.1080/2162402X.2015.1075692. PMID:27057447
   PubMed Web of Science ®Google Scholar
• Janikovits J, Müller M, Krzykalla J, Körner S, Echterdiek F, Lahrmann B, Grabe N, Schneider M, Benner A, Doeberitz M von K, et al. High numbers of PDCD1 (PD-1)-positive T cells and B2M mutations in microsatellite-unstable colorectal cancer. OncoImmunology. 2018;7(2):e1390640. doi:10.1080/2162402X.2017.1390640. PMID:29308317
   PubMed Web of Science ®Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13. doi:10.1126/science.aan6733. PMID:28596308
   PubMed Web of Science ®Google Scholar
• Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W, Sandoval S, Torrejon DY, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discovery. 2017;7(2):188–201. doi:10.1158/2159-8290.CD-16-1223. PMID:27903500
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Sherry RM, Schwartzentruber DJ, Topalian SL, Nicholas P, Filie A, Chang R, et al. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003;26(5):385–93. doi:10.1097/00002371-200309000-00001. PMID:12973027
   PubMed Web of Science ®Google Scholar
• Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly L, et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. New England Journal of Medicine. 2016;375(9):819–29. doi:10.1056/NEJMoa1604958. PMID:27433843
   PubMed Web of Science ®Google Scholar
• Giannakis M, Mu X, Shukla S, Qian Z, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell reports. 2016;15(4):857–65. doi:10.1016/j.celrep.2016.03.075.
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio Cancer Genomics Portal: An open platform for exploring multidimensional cancer genomics data. Cancer Discovery. 2012;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095. PMID:22588877
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Science Signaling. 2013;6(269):pl1–pl1. doi:10.1126/scisignal.2004088. PMID:23550210
   PubMed Web of Science ®Google Scholar
• Kloor M. Immunoselective Pressure and Human Leukocyte Antigen Class I Antigen Machinery Defects in Microsatellite Unstable Colorectal Cancers. Cancer Res. 2005;65(14):6418–24. doi:10.1158/0008-5472.CAN-05-0044. PMID:16024646
   PubMed Web of Science ®Google Scholar
• Woerner SM, Yuan YP, Benner A, Korff S, Von Knebel Doeberitz M, Bork P. SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res. 2009;38(SUPPL.1):682–9. doi:10.1093/nar/gkp839
   Google Scholar
• Koelzer VH, Baker K, Kassahn D, Baumhoer D, Zlobec I. Prognostic impact of β-2-microglobulin expression in colorectal cancers stratified by mismatch repair status. J Clin Pathol. 2012;65(11):996–1002. doi:10.1136/jclinpath-2012-200742. PMID:22859396
   PubMed Web of Science ®Google Scholar
• Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, et al. Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1. Genome Medicine. 2017;9(1):46. doi:10.1186/s13073-017-0434-0. PMID:28539123
   PubMedGoogle Scholar
• Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK, Wu J. JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 2013;3:3042. doi:10.1038/srep03042. PMID:24154688
   PubMed Web of Science ®Google Scholar
• Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, Yu L, Chmielecki J. Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion Reis RM, editor. PLOS ONE. 2017;12(11):e0176181. doi:10.1371/journal.pone.0176181. PMID:29121062
   PubMed Web of Science ®Google Scholar
• Czéh M, Loddenkemper C, Shalapour S, Schön C, Robine S, Goldscheid E, Stein H, Schüler T, Willimsky G, Blankenstein T. The immune response to sporadic colorectal cancer in a novel mouse model. Oncogene. 2010;29(50):6591–602. doi:10.1038/onc.2010.388. PMID:20818425
   PubMed Web of Science ®Google Scholar
• Meissner TB, Li A, Biswas A, Lee K-H, Liu Y-J, Bayir E, Iliopoulos D, van den Elsen PJ, Kobayashi KS. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes. Proc Natl Acad Sci. 2010;107(31):13794–9. doi:10.1073/pnas.1008684107.
   PubMed Web of Science ®Google Scholar
• Biswas A, Meissner TB, Kawai T, Kobayashi KS. Cutting Edge: Impaired MHC Class I Expression in Mice Deficient for Nlrc5/Class I Transactivator. J Immunol. 2012;189(2):516–20. doi:10.4049/jimmunol.1200064. PMID:22711889
   PubMed Web of Science ®Google Scholar
• Robbins GR, Truax AD, Davis BK, Zhang L, Brickey WJ, Ting JP-Y. Regulation of Class I Major Histocompatibility Complex (MHC) by Nucleotide-binding Domain, Leucine-rich Repeat-containing (NLR) Proteins. J Biol Chem. 2012;287(29):24294–303. doi:10.1074/jbc.M112.364604. PMID:22645137
   PubMed Web of Science ®Google Scholar
• Staehli F, Ludigs K, Heinz LX, Seguin-Estevez Q, Ferrero I, Braun M, Schroder K, Rebsamen M, Tardivel A, Mattmann C, et al. NLRC5 Deficiency Selectively Impairs MHC Class I- Dependent Lymphocyte Killing by Cytotoxic T Cells. J Immunol. 2012;188(8):3820–8. doi:10.4049/jimmunol.1102671. PMID:22412192
   PubMed Web of Science ®Google Scholar
• Tong Y, Cui J, Li Q, Zou J, Wang HY, Wang R-F. Enhanced TLR-induced NF-κB signaling and type I interferon responses in NLRC5 deficient mice. Cell Research. 2012;22(5):822–35. doi:10.1038/cr.2012.53. PMID:22473004
   PubMed Web of Science ®Google Scholar
• Yao Y, Wang Y, Chen F, Huang Y, Zhu S, Leng Q, Wang H, Shi Y, Qian Y. NLRC5 regulates MHC class I antigen presentation in host defense against intracellular pathogens. Cell Research. 2012;22(5):836–47. doi:10.1038/cr.2012.56. PMID:22491475
   PubMed Web of Science ®Google Scholar
• Chelbi ST, Guarda G. NLRC5, a promising new entry in tumor immunology. Journal for ImmunoTherapy of Cancer. 2016;4(1):39. doi:10.1186/s40425-016-0143-z. PMID:27437103
   PubMedGoogle Scholar
• Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci. 2016;113(21):5999–6004. doi:10.1073/pnas.1602069113.
   PubMed Web of Science ®Google Scholar
• Chelbi ST, Dang AT, Guarda G. Emerging Major Histocompatibility Complex Class I-Related Functions of NLRC5. Adv Immunol. 2017;133:89–119. doi:10.1016/bs.ai.2016.11.003
   Google Scholar
• de Kruijf EM, van Nes JGH, Sajet A, Tummers QRJG, Putter H, Osanto S, Speetjens FM, Smit VTHBM, Liefers GJ, van de Velde CJH, et al. The Predictive Value of HLA Class I Tumor Cell Expression and Presence of Intratumoral Tregs for Chemotherapy in Patients with Early Breast Cancer. Clin Cancer Res. 2010;16(4):1272–80. doi:10.1158/1078-0432.CCR-09-1844. PMID:20145162
   PubMed Web of Science ®Google Scholar